image

FIND A COURSE

  • The ASAM National Practice Guideline Special Populations Webinar (October)

    Includes a Live Event on 10/25/2016 at 3:00 PM (EDT)

    Adolescents - This webinar will provide important recommendations to help clinicians treat adolescents who have complex medical and environmental needs.

    This special populations webinar series follows the National Practice Guideline overview webinar which outlined the recommendations from ASAM's National Practice Guideline for the Use of Medications in the Treatment of Opioid Use Disorders, which is the first guideline to include all medications to treat opioid use disorder.

    The treatment of adolescents with opioid use disorder presents many unique medical, legal, and ethical dilemmas that may complicate treatment. Given these unique issues, adolescents with opioid use disorder often benefit from services designed specifically for them. The Adolescents Webinar will provide an overview of the recommendation and in-depth information treating adolescents from ASAM's National Practice Guideline.


    This webinar is primarily intended for clinicians involved in evaluating patients and providing authorization for pharmacological treatments at any level.

    At the conclusion of the webinar, participants should be able to:

    • Recognize epidemiology of opioid use disorder and the treatment gap among patients misusing opioids and heroin.
    • Summarize the guideline's treatment recommendations for special populations and discuss how they should be used in practice.
    • Identify the fundamental components of an OUD patient assessment and diagnosis for special populations with opioid use disorders.
    • Discuss the unique needs and treatment recommendations for adolescents.

    The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    ASAM designates this live activity for a maximum of .75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    American Board of Addiction Medicine (ABAM) MOC:

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of .75 AMA PRA Category 1 Credits™.

    CME Committee

    Name Disclosure Information
    Adam J. Gordon, MD, MPH, FACP, FASAM, CMRO, Chair None

    Catherine Friedman, MD, Vice Chair, Reviewer

    None
    Noel Ilogu, MD, MRCP None
    Herbert L. Malinoff, MD, FACP, FASAM None
    Edwin A. Salsitz, MD, FASAM, Reviewer None
    John C. Tanner, DO, FASAM, CCFC, MRO

    Reckitt-Benckiser: Honorarium, Speaker

    Orexo: Honorarium, Speaker

    BDSI: Honorarium, Speaker & Consultant

    Planning Committee

    Name Disclosure Information
    Adam J. Gordon, MD, MPH, FACP, FASAM, CMRO None
    Margaret A. E. Jarvis, MD, FASAM

    Geisinger Health System: Salary, Medical Director

    US Preventive Health: Dividend, Stockholder

    Hoffspiegel and Associates: Fees, Expert Witness

    Up-to-Date: Royalties, Author

    Robert J. Roose, MD, MPH Health New England, Inc.: Honorarium, Behavioral Health Advisory Committee, Associate Medical Director

    Faculty

    Name Disclosure Information
    Marc Fishman, MD, DFASAM

    Maryland Treatment Centers: Employment, Ownership Interest includes stock, stock options, patent or other intellectual property

    US World Meds: Consultant/Advisory Board, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

    Aaron D. Fox, MD, MS None
    Brian Hurley, MD, MBA, DFASAM None
    Yngvild Olsen, MD, MPH, FASAM None
    Tricia Wright, MD, MS, FACOG, FASAM None

    Marc Fishman

    MD, DFASAM

    Marc Fishman MD is board certified in addiction psychiatry and addiction medicine. A faculty member of the Johns Hopkins University School of Medicine, he is Medical Director and CEO of Maryland Treatment Centers, a regional behavioral health care provider, with inpatient and outpatient facilities for adolescents and adults. His clinical specialties include treatment of drug-involved and dual-diagnosis adolescents, opioid dependence in adolescents and adults, and co-occurring disorders. He has been principal investigator or collaborator for several NIDA- and CSAT-funded projects to improve and evaluate adolescent treatment, as well as pharmacotherapy trials in adults. He is the author of numerous articles and book chapters on addiction treatment, and lectures widely on a variety of topics including adolescent treatment, youth opioid treatment, placement and treatment matching strategies. Dr. Fishman served as a co-editor for the most recent editions of ASAMs Patient Placement Criteria, leading the adolescent section, and served as the chief editor for the ASAM PPC Supplement on Pharmacotherapies for Alcohol Use Disorders. He is the chair of the Adolescent Committee for ASAM. He is a Past President of the Maryland Society of Addiction Medicine.

    • Register
      • Regular Member - Free!
      • Retired - Free!
      • Early Career Physician - Free!
      • Resident - Free!
      • Student - Free!
      • Associate - Free!
      • ASAM Staff - Free!
      • Non-Member - Free!
      • International Member - Free!
      • Emeritus Member - Free!
      • Provisional Member - Free!
      • Fellow Member - Free!
      • Honorary Member - Free!
    • More Information
  • The ASAM National Practice Guideline Special Populations Webinar (September)

    Includes a Live Event on 09/27/2016 at 12:00 PM (EDT)

    Individuals with Pain - This webinar will provide important recommendations to help clinicians treat individuals with pain who have complex medical and environmental needs.

    This special populations webinar series follows the National Practice Guideline overview webinar which outlined the recommendations from ASAM's National Practice Guideline for the Use of Medications in the Treatment of Opioid Use Disorders, which is the first guideline to include all medications to treat opioid use disorder.

    The occurrence of acute and chronic pain among patients with an opioid use disorder is not uncommon. Because of the current epidemic of nonmedical prescription drug use, it is critical to know how to manage pain safely and effectively. The Individuals with Pain Webinar will provide an overview of the recommendations and in-depth information on treating individuals with pain from ASAM's National Practice Guideline.


    This webinar is primarily intended for clinicians involved in evaluating patients and providing authorization for pharmacological treatments at any level.

    At the conclusion of the webinar, participants should be able to:

    • Recognize epidemiology of opioid use disorder and the treatment gap among patients misusing opioids and heroin.
    • Summarize the guideline's treatment recommendations for special populations and discuss how they should be used in practice.
    • Identify the fundamental components of an OUD patient assessment and diagnosis for special populations with opioid use disorders.
    • Discuss the unique needs and treatment recommendations for individuals with pain.

    The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    ASAM designates this live activity for a maximum of .75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    American Board of Addiction Medicine (ABAM) MOC:

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of .75 AMA PRA Category 1 Credits™.

    CME Committee

    Name Disclosure Information
    Adam J. Gordon, MD, MPH, FACP, FASAM, CMRO, Chair None

    Catherine Friedman, MD, Vice Chair, Reviewer

    None
    Noel Ilogu, MD, MRCP None
    Herbert L. Malinoff, MD, FACP, FASAM None
    Edwin A. Salsitz, MD, FASAM, Reviewer None
    John C. Tanner, DO, FASAM, CCFC, MRO

    Reckitt-Benckiser: Honorarium, Speaker

    Orexo: Honorarium, Speaker

    BDSI: Honorarium, Speaker & Consultant

    Planning Committee

    Name Disclosure Information
    Adam J. Gordon, MD, MPH, FACP, FASAM, CMRO None
    Margaret A. E. Jarvis, MD, FASAM

    Geisinger Health System: Salary, Medical Director

    US Preventive Health: Dividend, Stockholder

    Hoffspiegel and Associates: Fees, Expert Witness

    Up-to-Date: Royalties, Author

    Robert J. Roose, MD, MPH Health New England, Inc.: Honorarium, Behavioral Health Advisory Committee, Associate Medical Director

    Faculty

    Name Disclosure Information
    Marc Fishman, MD, DFASAM

    Maryland Treatment Centers: Employment, Ownership Interest includes stock, stock options, patent or other intellectual property

    US World Meds: Consultant/Advisory Board, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

    Aaron D. Fox, MD, MS None
    Brian Hurley, MD, MBA, DFASAM None
    Yngvild Olsen, MD, MPH, FASAM None
    Tricia Wright, MD, MS, FACOG, FASAM None

    Yngvild Olsen

    MD, MPH, FASAM

    Yngvild Olsen, MD, MPH, currently serves as Medical Director of the Institutes for Behavior Resources Inc/REACH Health Services, a comprehensive outpatient Opioid Treatment Program in Baltimore City. She completed her medical training at Harvard Medical School, and internal medicine residency with a year as Primary Care Chief Resident at the Boston Medical Center. She received a Master's in Public Health from the Johns Hopkins University Bloomberg School of Public Health as part of a fellowship in General Internal Medicine at the Johns Hopkins School of Medicine. She has previously served as the Vice President of Clinical Affairs for the Baltimore Substance Abuse Systems, as the Deputy Health Officer for the Harford County Health Department, and as the Medical Director for the Johns Hopkins Hospital's outpatient substance use treatment services. Dr. Olsen's advocacy work includes serving as the President of the Maryland Society of Addiction Medicine (MDSAM), as the President of the Maryland Association for the Treatment of Opioid Dependence (MATOD), and as a member of several boards and councils, including the Maryland Overdose Prevention Advisory Council, the Journey Home Board, Baltimore's effort to end homelessness, and the National Council on Alcoholism and Other Drug Dependence-Maryland chapter board. She also proudly looks forward to serving as a recently elected At-Large Member to the ASAM Board of Directors for 2015-2017.

    • Register
      • Regular Member - Free!
      • Retired - Free!
      • Early Career Physician - Free!
      • Resident - Free!
      • Student - Free!
      • Associate - Free!
      • ASAM Staff - Free!
      • Non-Member - Free!
      • International Member - Free!
      • Emeritus Member - Free!
      • Provisional Member - Free!
      • Fellow Member - Free!
      • Honorary Member - Free!
    • More Information
  • The ASAM National Practice Guideline Special Populations Webinar (August)

    Includes a Live Event on 08/30/2016 at 3:00 PM (EDT)

    Individuals in the Criminal Justice System - This webinar will provide important recommendations to help clinicians treat individuals in the criminal justice system with opioid use disorder who have complex medical and environmental needs.

    This special populations webinar series follows the National Practice Guideline overview webinar which outlined the recommendations from ASAM's National Practice Guideline for the Use of Medications in the Treatment of Opioid Use Disorders, which is the first guideline to include all medications to treat opioid use disorder.

    A substantial proportion of persons in prisons, jails, drug courts, probation, parole, and who are criminally involved have opioid use disorder and related problems. Prison drug use is particularly risky because of the environment. The high concentration of at-risk individuals and general overcrowding can increase the risk of adverse consequences associated with drug use, including violence, drug-related deaths, suicide, and self-harm. The Individuals in the Criminal Justice System webinar will provide an overview of the recommendations and in-depth information on treating individuals in the criminal justice system from ASAM's National Practice Guideline.


    This webinar is primarily intended for clinicians involved in evaluating patients and providing authorization for pharmacological treatments at any level.

    At the conclusion of the webinar, participants should be able to:

    • Recognize epidemiology of opioid use disorder and the treatment gap among patients misusing opioids and heroin.
    • Summarize the guideline's treatment recommendations for special populations and discuss how they should be used in practice.
    • Identify the fundamental components of an OUD patient assessment and diagnosis for special populations with opioid use disorders.
    • Discuss the unique needs and treatment recommendations for individuals in the criminal justice system.

    The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    ASAM designates this live activity for a maximum of .75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    American Board of Addiction Medicine (ABAM) MOC:

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of .75 AMA PRA Category 1 Credits™.

    CME Committee

    Name Disclosure Information
    Adam J. Gordon, MD, MPH, FACP, FASAM, CMRO, Chair None

    Catherine Friedman, MD, Vice Chair, Reviewer

    None
    Noel Ilogu, MD, MRCP None
    Herbert L. Malinoff, MD, FACP, FASAM None
    Edwin A. Salsitz, MD, FASAM, Reviewer None
    John C. Tanner, DO, FASAM, CCFC, MRO

    Reckitt-Benckiser: Honorarium, Speaker

    Orexo: Honorarium, Speaker

    BDSI: Honorarium, Speaker & Consultant

    Planning Committee

    Name Disclosure Information
    Adam J. Gordon, MD, MPH, FACP, FASAM, CMRO None
    Margaret A. E. Jarvis, MD, FASAM

    Geisinger Health System: Salary, Medical Director

    US Preventive Health: Dividend, Stockholder

    Hoffspiegel and Associates: Fees, Expert Witness

    Up-to-Date: Royalties, Author

    Robert J. Roose, MD, MPH Health New England, Inc.: Honorarium, Behavioral Health Advisory Committee, Associate Medical Director

    Faculty

    Name Disclosure Information
    Marc Fishman, MD, DFASAM

    Maryland Treatment Centers: Employment, Ownership Interest includes stock, stock options, patent or other intellectual property

    US World Meds: Consultant/Advisory Board, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

    Aaron D. Fox, MD, MS None
    Brian Hurley, MD, MBA, DFASAM None
    Yngvild Olsen, MD, MPH, FASAM None
    Tricia Wright, MD, MS, FACOG, FASAM None

    Aaron D. Fox

    MD, MS

    Aaron Fox is an Assistant Professor of Medicine in the Division of General Internal Medicine at Albert Einstein College of Medicine/Montefiore Medical Center. Dr. Fox is a primary care physician and is Board Certified in Addiction Medicine. He completed residency training at Montefiore in the Primary Care/Social Medicine Residency Program and also received a Master's Degree in Clinical Research Methods from Einstein. Dr. Fox is the Co-Director of the Bronx Transitions Clinic, which provides medical care to patients who have recently been released from jail or prison. He also conducts research, funded by the National Institute on Drug Abuse, on opioid use disorder and the criminal justice system, developing behavioral interventions to complement buprenorphine treatment for opioid use disorder; and studying linkage to medical care following release from jail or prison.

    • Register
      • Regular Member - Free!
      • Retired - Free!
      • Early Career Physician - Free!
      • Resident - Free!
      • Student - Free!
      • Associate - Free!
      • ASAM Staff - Free!
      • Non-Member - Free!
      • International Member - Free!
      • Emeritus Member - Free!
      • Provisional Member - Free!
      • Fellow Member - Free!
      • Honorary Member - Free!
    • More Information
  • The ASAM National Practice Guideline Special Populations Webinar (June)

    Recorded On: 06/21/2016

    Individuals with Co-occurring Psychiatric Disorders - This webinar will provide important recommendations to help clinicians treat individuals with co-occurring psychiatric disorders who have complex medical and environmental needs.

    This special populations webinar series follows the National Practice Guideline overview webinar which outlined the recommendations from ASAM's National Practice Guideline for the Use of Medications in the Treatment of Opioid Use Disorders, which is the first guideline to include all medications to treat opioid use disorder.

    Co-occurring psychiatric disorders are common among individuals who have opioid use disorder. Studies have demonstrated a higher prevalence of substance use among people with psychiatric disorders relative to the general population. The Individuals with Co-occurring Psychiatric Disorders Webinar will provide an overview of the recommendations and in-depth information on treating individuals with co-occurring psychiatric disorders from ASAM's National Practice Guideline.


    This webinar is primarily intended for clinicians involved in evaluating patients and providing authorization for pharmacological treatments at any level.

    At the conclusion of the webinar, participants should be able to:

    • Recognize epidemiology of opioid use disorder and the treatment gap among patients misusing opioids and heroin.
    • Summarize the guideline's treatment recommendations for special populations and discuss how they should be used in practice.
    • Identify the fundamental components of an OUD patient assessment and diagnosis for special populations with opioid use disorders.
    • Discuss the unique needs and treatment recommendations for individuals with co-occurring psychiatric disorders.

    The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    ASAM designates this live activity for a maximum of .75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    American Board of Addiction Medicine (ABAM) MOC:

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of .75 AMA PRA Category 1 Credits™.

    CME Committee

    Name Disclosure Information
    Adam J. Gordon, MD, MPH, FACP, FASAM, CMRO, Chair, Reviewer None

    Catherine Friedman, MD, Vice Chair, Reviewer

    None
    Noel Ilogu, MD, MRCP None
    Herbert L. Malinoff, MD, FACP, FASAM None
    Edwin A. Salsitz, MD, FASAM, Reviewer None
    John C. Tanner, DO, FASAM, CCFC, MRO

    Reckitt-Benckiser: Honorarium, Speaker

    Orexo: Honorarium, Speaker

    BDSI: Honorarium, Speaker & Consultant

    Planning Committee

    Name Disclosure Information
    Adam J. Gordon, MD, MPH, FACP, FASAM, CMRO None
    Margaret A. E. Jarvis, MD, FASAM

    Geisinger Health System: Salary, Medical Director

    US Preventive Health: Dividend, Stockholder

    Hoffspiegel and Associates: Fees, Expert Witness

    Up-to-Date: Royalties, Author

    Robert J. Roose, MD, MPH Health New England, Inc.: Honorarium, Behavioral Health Advisory Committee, Associate Medical Director

    Faculty

    Name Disclosure Information
    Marc Fishman, MD, DFASAM

    Maryland Treatment Centers: Employment, Ownership Interest includes stock, stock options, patent or other intellectual property

    US World Meds: Consultant/Advisory Board, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

    Aaron D. Fox, MD, MS None
    Brian Hurley, MD, MBA, DFASAM None
    Yngvild Olsen, MD, MPH, FASAM None
    Tricia Wright, MD, MS, FACOG, FASAM None

    Brian Hurley

    MD, MBA, DFASAM

    Brian Hurley, MD, MBA is a Veterans Administration National Quality Scholar affiliated with the University of California, Los Angeles (UCLA) at the VA Greater Los Angeles Healthcare System, and will be a 2015-2017 Robert Wood Johnson Foundation Clinical Scholar at UCLA. He completed a fellowship program in addiction psychiatry at New York University School of Medicine. He completed residency training at the Massachusetts General Hospital and McLean Hospital (MGH-McLean), where he was Chief Resident in Addiction Psychiatry. Brian applied to medical school with the explicit intention of becoming an addiction physician. He joined ASAM in 2002 as a first year medical student, and has served on the ASAM Board of Directors in various capacities since 2003. He currently serves as the co-chair of ASAM's Membership Committee and serves on ASAM's Finance Committee. He previously served as chair of ASAM's Physicians-in-Training Committee Chair and is formerly ASAM's alternate delegate to the American Medical Association. Brian additionally served on the EVP/CEO search committee in 2010 that led to Penny Mill's selection as ASAM's current EVP/CEO. He has additional served in various roles for the Massachusetts Society of Addiction Medicine, New York Society of Addiction Medicine, and California Society of Addiction Medicine. Aside from ASAM, Brian is a former National President of the American Medical Student Association. He is a 2012 American College of Psychiatrists Laughlin fellow, a 2010-2013 American Psychiatric Association (APA) Public Psychiatry Fellow, and a 2015-2017 Group for Advancement of Psychiatry Fellow. Brian also serves on the American Medical Colleges' Advisory Committee on Sexual Orientation, Gender Identity, and Sex Development. He is also the Gay and Lesbian Medical Association's delegate to the American Medical Association's (AMA's) House of Delegates. Brian has previously served on the Board of Trustees of the APA.

    • Register
      • Regular Member - Free!
      • Retired - Free!
      • Early Career Physician - Free!
      • Resident - Free!
      • Student - Free!
      • Associate - Free!
      • ASAM Staff - Free!
      • Non-Member - Free!
      • International Member - Free!
      • Emeritus Member - Free!
      • Provisional Member - Free!
      • Fellow Member - Free!
      • Honorary Member - Free!
    • More Information
  • ASAM 47th Annual Conference - Innovations in Addiction Medicine and Science - 2016 (69 CME)

    To present the most up-to-date information, research, guidance and policy discussion for professionals in the addiction medicine field.

    The ASAM Annual Conference is the nation's premiere event providing the latest innovations and scientific developments in addiction medicine. The program includes exciting changes in format and structure to provide learning in a more interactive, casual and fun environment.

    Meeting highlights include; symposia, workshops, poster presentations, special focus sessions and fun events designed to allow more effective learning and networking. Participate in the front-running conference that specializes in addiction medicine:

    • Learn about new tools for diagnosis, treatment, patient care and public policy
    • Explore the newest research and developments shaping the future of addiction medicine
    • Network with medical professionals, researchers, leading scientists and policy advocates
    • Find out about the latest science from leaders of federal agencies and institutions
    • Discover evidence-based techniques, tools, technologies and practices
    • Engage in discussions about strategies of integration of addiction medicine and primary care
    • Participate in special on and off-site sessions that dive into substance use in Baltimore and the programs that seek to address it.

    Annual Conference Presenters

    Name

    Disclosure Information

    Anthony J. Accurso, MD

    Nothing to Disclose

    Arpana Agrawal, PhD

    Nothing to Disclose

    Barbara Andraka-Christou, JD

    Nothing to Disclose

    Elie Aoun, MD

    Nothing to Disclose

    Soraya Asadi, MD, DABAM

    Nothing to Disclose

    Genie L. Bailey, MD

    Nothing to Disclose

    Joshua Barclay, MD, MS, MSHR, FACP

    Nothing to Disclose

    Gabriela Barnett, MA

    Nothing to Disclose

    Gavin Bart, MD PhD FASAM FACP

    Nothing to Disclose

    Kaitlan Baston, MD

    Nothing to Disclose

    Lou Baxter, MD, FASAM

    Nothing to Disclose

    Inna Belfer, MD, PhD

    Nothing to Disclose

    Lia Bennett, MPH

    Nothing to Disclose

    Michael F Bierer, MD MPH

    Nothing to Disclose

    Adam Bisaga, MD

    Alkermes, Inc (Self) : Other Financial or Material Support (Status: Ongoing), received research suport (Status: Ongoing)

    Richard D. Blondell, MD

    Nothing to Disclose

    Katharine Bradley, MD MPH

    Nothing to Disclose

    Adam C. Brooks, PhD

    Nothing to Disclose

    E Marshall Brooks, PhD

    Nothing to Disclose

    Lawrence S. Brown, MD, MPH, FASM

    CDC Foundation: Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

    Randall Brown, MD, PhD, FASAM

    Nothing to Disclose

    Richard Brown, MD, MPH

    Wellsys, LLC: Ownership Interest includes stock, stock options, patent or other intellectual property

    Greg Bunt, MD

    Nothing to Disclose

    Rachael Burgower, MA

    Nothing to Disclose

    Ryan Caldeiro, MD

    Nothing to Disclose

    Melinda Campopiano, MD

    Nothing to Disclose

    Katherine V. Carroll, PA-C

    Nothing to Disclose

    Mady Chalk, PhD, MSW

    Nothing to Disclose

    Yuchiao Chang, PhD

    Nothing to Disclose

    Faye Chao, MD

    Nothing to Disclose

    Margaret S. Chisolm, MD

    Nothing to Disclose

    Veronic Clair, MD, MSc, CCFP, FRCPC, PhD

    Nothing to Disclose

    H. Westley Clark, MD, JD, MPH, FASAM

    Nothing to Disclose

    Kelly Clark, MD, MBA, FASAM

    Nothing to Disclose

    Diana Coffa, MD

    Nothing to Disclose

    Stephen Colameco, MD, MEd, FASAM

    Nothing to Disclose

    Sophie Collins, MD

    Nothing to Disclose

    Wilson M. Compton, MD, MPE

    3M Corp.: Ownership Interest includes stock, stock options, patent or other intellectual property

    General Electric Co.: Ownership Interest includes stock, stock options, patent or other intellectual property

    Pfizer, Inc.: Ownership Interest includes stock, stock options, patent or other intellectual property

    Micah T. Conti, BA

    Nothing to Disclose

    Roxanne Cook, RN

    Nothing to Disclose

    Desiree A Crevecoeur-MacPhail, PhD

    Nothing to Disclose

    Andrew A. Danzo,

    Nothing to Disclose

    Smita Das, MD

    Nothing to Disclose

    Amy Davis, DO, MS, FACP, FAAHPM

    Nothing to Disclose

    Corey Davis, JD, MSPH

    Nothing to Disclose

    Michael A. Dekker, DO

    Nothing to Disclose

    Caroline M. DuPont, MD

    Nothing to Disclose

    Paul H. Earley, MD, DFASAM

    Alkermes, Inc.: Speaker/Honoraria includes speakers bureau, symposia, and expert witness

    Earley COnsulatncy, LLC: Employment

    Georgia Professionals Health Program: Employment

    RiverMend Health : Consultant/Advisory Board

    Ryan Eisenacher,

    Nothing to Disclose

    Sheri Eisert, PhD

    Nothing to Disclose

    Honora Englander, MD

    Nothing to Disclose

    David H. Epstein, PhD

    Nothing to Disclose

    Igor Epstein, DO

    Nothing to Disclose

    Anthony Estreet, PhD

    Nothing to Disclose

    Oluwaseun Falade, MD

    Nothing to Disclose

    Patrick Fehling, MD

    Nothing to Disclose

    David Festinger, PhD

    Nothing to Disclose

    David A. Fiellin, MD

    Pinney Associates: Consultant/Advisory Board

    Michael Fingerhood, MD

    Nothing to Disclose

    Marc Fishman, MD, FASAM

    Maryland Treatment Centers: Employment, Ownership Interest includes stock, stock options, patent or other intellectual property

    US World Meds: Consultant/Advisory Board, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

    Jessica N. Flori, BA

    Nothing to Disclose

    Thomas E. Freese, PhD

    Nothing to Disclose

    John Fromson, MD

    Nothing to Disclose

    Jessie Gaeta, MD

    Nothing to Disclose

    Marc Galanter, MD

    Nothing to Disclose

    Eliot L. Gardner, PhD

    Nothing to Disclose

    David R. Gastfriend, MD

    Nothing to Disclose

    Shareh Ghani, MD

    Nothing to Disclose

    Udi Ghitza, PhD

    Nothing to Disclose

    David Goldman, MD

    Nothing to Disclose

    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAM

    Center for Health & Innovation Learning (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Hazelden Betty Ford Foundation (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing)

    David A. Gorelick, MD, PhD, DLFAPA

    Nothing to Disclose

    Kevin Gray, MD

    Nothing to Disclose

    William Greaves, MD, MSPH

    Nothing to Disclose

    Traci Green, PhD, MSc

    Nothing to Disclose

    Mark K. Greenwald, PhD

    Indivior: Consultant/Advisory Board, Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support, Speaker/Honoraria includes speakers bureau, symposia, and expert witness

    Jessica Gregg, MD, PhD

    Nothing to Disclose

    Allison F. Hall, BS

    Nothing to Disclose

    Susan Hayashi, PhD

    Nothing to Disclose

    Gary Henschen, MD LFAPA

    Nothing to Disclose

    Sara K. Hertzel, BA

    Nothing to Disclose

    Marilyn A. Huestis, PhD

    Nothing to Disclose

    Andrew Huff, LPC

    Nothing to Disclose

    Brian Hurley, MD, MBA

    Nothing to Disclose

    Polly Ingram, BA

    Nothing to Disclose

    Krystyna R. Isaacs, PhD

    Nothing to Disclose

    J Harry Isaacson, MD

    Nothing to Disclose

    Benjamin D. Johnson, DO

    Nothing to Disclose

    Matthew W. Johnson, PhD

    Nothing to Disclose

    Hendree E. Jones, PhD

    Nothing to Disclose

    Jolene Joseph, LISW

    Nothing to Disclose

    Alene Kennedy-Hendricks, PhD

    Nothing to Disclose

    Jag H. Khalsa, MS, PhD

    Nothing to Disclose

    Sonnie Kim, PharmD

    Braeburn Pharmaceuticals: Employment

    Kaylin Klie, MD

    Nothing to Disclose

    Andrea Kline-Simon, MS

    Nothing to Disclose

    George Kolodner, MD

    Nothing to Disclose

    Philip Todd. Korthuis, MD, MPH

    Nothing to Disclose

    Henry R. Kranzler, MD

    Alkermes: Consultant/Advisory Board

    Lundbeck Pharmaceuticals: Consultant/Advisory Board, Speaker/Honoraria includes speakers bureau, symposia, and expert witness

    Member of Amer Soc Clin Psychopharmacology's Alcohol Clinical Trials Initiative, supported by Alkermes, Lilly, Lundbeck, AbbVie, and Ethypharm : Consultant/Advisory Board

    Otsuka Pharmaceuticals: Consultant/Advisory Board

    Mark l. Kraus, MDDFASAM

    Nothing to Disclose

    Kevin Kunz, MD

    Nothing to Disclose

    JoAn Laes, MD

    Nothing to Disclose

    Shenghan Lai, MD, MPH

    Nothing to Disclose

    Bernard Le Foll, MD, PhD, MCFP

    Bioprojet: Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

    GW pharma: Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support

    Mettrum: Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

    Pfizer: Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

    Joshua D. Lee, MD, MSc

    Alkermes, Inc: Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

    Anne Leopold, MSc

    Nothing to Disclose

    Petros Levounis, MD, MA

    Nothing to Disclose

    Chris Lewis, MA

    Nothing to Disclose

    Thomas Lincoln, MD

    Nothing to Disclose

    Raye Z. Litten, PhD

    Nothing to Disclose

    Michelle Lofwall, MD

    Braeburn: Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

    CVS Caremark: Consultant/Advisory Board

    Orexo: Consultant/Advisory Board

    PCM Scientific: Speaker/Honoraria includes speakers bureau, symposia, and expert witness

    David Lott, MD, FAPA, FASAM

    Nothing to Disclose

    Peter Luongo, PhD

    Nothing to Disclose

    Lauren MacAfee, MD

    Nothing to Disclose

    Jose R. Maldonado, MD, FAPM, FACFE

    Nothing to Disclose

    Herbert L Malinoff, MD, FACP, DFASAM

    Nothing to Disclose

    Ajay Manhapra, MD

    Nothing to Disclose

    Alex Manini, MD, MS

    Nothing to Disclose

    David Marcovitz, MD

    Nothing to Disclose

    Laura Martin, MD

    Nothing to Disclose

    Steven C. Matson, MD

    Nothing to Disclose

    Alexis K Matusiewicz, PhD

    Nothing to Disclose

    David Mee-Lee, MD

    Nothing to Disclose

    Kathleen Meyers, PhD

    Nothing to Disclose

    Jennifer Michaels, MD

    Nothing to Disclose

    David Miller, MD

    Nothing to Disclose

    William R Miller, PhD

    Guilford Press (Self) : Royalties (Status: Ongoing)

    Ivan Montoya, MD, MPH

    Nothing to Disclose

    Landhing M. Moran, PhD

    Nothing to Disclose

    Dan Morhaim, MD

    Nothing to Disclose

    Warren Morris, MD FASAM

    Nothing to Disclose

    Howard B. Moss, MD

    Nothing to Disclose

    Sam Muszynski, JD

    Nothing to Disclose

    Lewis Nelson, MD

    Nothing to Disclose

    Doug Nemecek, MD, MBA

    Nothing to Disclose

    Edward Nunes, MD

    Nothing to Disclose

    Patrick O'Connor, MD, MPH, FACP

    Nothing to Disclose

    Yngvild Olsen, MD, MPH

    Nothing to Disclose

    Nicholas A. Pace, MD

    Nothing to Disclose

    Patricia Pade, MD

    Nothing to Disclose

    Stephen Patrick, MD, MPH, MS

    Vermont Oxford Network (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- 12/2015)

    Joseph Perpich, MD, JD

    Nothing to Disclose

    Heather Peterson, PA-C

    Nothing to Disclose

    Karran Phillips, MD, MSc

    Nothing to Disclose

    Mel Pohl, MD, FASAM

    Las Vegas Recovery Center: Employment

    Cara Poland, MD, MEd

    Nothing to Disclose

    Sabrina Poole, PsyD

    Nothing to Disclose

    Lantie Quinones, MD

    Nothing to Disclose

    Darius Rastegar, MD

    Nothing to Disclose

    James Ray, PharmD

    Alchemy Consulting, P.C.: Ownership Interest includes stock, stock options, patent or other intellectual property

    Michael D Reisman, JD

    Nothing to Disclose

    Traci Rieckmann, PhD

    Nothing to Disclose

    Richard K. Ries, MD

    Nothing to Disclose

    Megan M. Risi, BS

    Nothing to Disclose

    Deidra Y Roach, MD

    Nothing to Disclose

    Maureen Roberts, MD

    Nothing to Disclose

    Sarah CM. Roberts, DrPH

    Nothing to Disclose

    Naoko A. Ronquest, PhD

    Nothing to Disclose

    Robert Roose, MD, MPH, FASAM

    Nothing to Disclose

    Richard N. Rosenthal, MD

    Braeburn Pharmaceticals: Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

    Alphonse Ken Roy, MD, FASAM, DLFAPA

    Nothing to Disclose

    Payel Roy, MD

    Nothing to Disclose

    Gregory Rudolf, MD, FASAM

    Nothing to Disclose

    Beth A. Rutkowski, MPH

    Nothing to Disclose

    Kelley Saia, MD,

    Nothing to Disclose

    Richard Saitz, MD, MPH, FASAM

    Nothing to Disclose

    Edwin A. Salsitz, MD, DFASAM

    Nothing to Disclose

    Ruchi Sanghani, MA

    Nothing to Disclose

    Rebekah Savage, MD, MPH

    Nothing to Disclose

    Zev Schuman-Olivier, MD

    Nothing to Disclose

    Robert Schwartz, MD

    Reckitt Benckiser: Consultant/Advisory Board

    Daniel A. Schwarz, MD, CMRO

    Nothing to Disclose

    Peter Selby, MBBS, FCFP, dipABAM

    Bristol Meyer Squibb: Speaker/Honoraria includes speakers bureau, symposia, and expert witness

    Johnson and Johnson: Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support

    Pfizer: Consultant/Advisory Board, Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

    Nadav Shalit, MD

    Nothing to Disclose

    Randi G. Sokol, MD, MPH, MMedEd

    Nothing to Disclose

    Robert Sokol, MD

    Nothing to Disclose

    Rachel Solotarof, MD, MCR

    Nothing to Disclose

    Christopher Stauffer, MD

    Nothing to Disclose

    Robert Sterling, PhD

    Nothing to Disclose

    Kenneth Stoller, MD

    Nothing to Disclose

    Geetha Subramaniam, MD, DFAPA

    Nothing to Disclose

    Angela Suen, BS

    Nothing to Disclose

    Brian Suffoletto, MD, MS

    healthStratica (Self) : Royalties (Status: Ongoing)

    Fatimah Tahil, MD, MPH, DFAPA, FAPM

    Nothing to Disclose

    John Teal, MD

    Nothing to Disclose

    Mishka Terplan, MD, MPH, FACOG, FASAM

    Nothing to Disclose

    Sebastian T. Tong, MD, MPH

    Nothing to Disclose

    Paul A. Trowbridge, MD, MPH

    Nothing to Disclose

    Allison Verbyla, MPH Candidate

    Nothing to Disclose

    Annmarie Lyn. Vilkins, DO, MSc

    Nothing to Disclose

    Hoa Vo, PhD

    Nothing to Disclose

    Frank Vocci, PhD

    Braeburn Pharmaceuticals: Consultant/Advisory Board, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

    Demerx: Consultant/Advisory Board

    Pinney Associates: Consultant/Advisory

    Reckitt-Benckiser Pharmaceuticals: Consultant/Advisory Board, Speaker/Honoraria includes speakers bureau, symposia, and expert witness

    Nora D Volkow, MD

    Nothing to Disclose

    Sarah E. Wakeman, MD

    Nothing to Disclose

    Alexander Y. Walley, MD, MSc

    Nothing to Disclose

    James Walsh, MD

    Nothing to Disclose

    Vickie Walters, LCSW-C

    Nothing to Disclose

    Mark Ware, BA, MBBS, MRCP(UK), MSc

    Canadian Consortium for the Investigation of Cannabinoids : Employment

    CanniMed: Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

    Damien Christopher Warsavage, YE-CRS, CRS

    Nothing to Disclose

    Michael F. Weaver, MD, FASAM

    Nothing to Disclose

    Melissa Weimer, DO, MCR

    Nothing to Disclose

    Mark A Weiner, MD, DFASAM

    Nothing to Disclose

    Constance Weisner, DrPH, LCSW

    Nothing to Disclose

    Leana Wen, MD, MSc

    Nothing to Disclose

    Joseph Westermeyer, MD, PhD, MPH

    Nothing to Disclose

    Timothy Wiegand, MD, DABAM, FACMT, FAACT

    Nothing to Disclose

    Bonnie b. Wilford, MS

    Nothing to Disclose

    Jeffrey Wilkins, MD, FASAM, DFAPA

    Nothing to Disclose

    Justin Wolfe, MSW, LCSW, CADC

    Nothing to Disclose

    Li-Tzy Wu, ScD RN MA

    Nothing to Disclose

    Martha J. Wunsch, MD FAAP FASAM

    Nothing to Disclose

    Stephen Wyatt, DO

    Nothing to Disclose

    Annual Conference Planning Committee

    Name

    Disclosure Information

    Anthony Paul Albanese, MD, DFASAM

    Gilead Sciences: speaker/ad board, honorarium; AbbVie Pharmaceuticals: speaker/ad board, honorarium; Merck Pharmaceuticals: speaker/ad board, honorarium; Genentech Pharmaceuticals: speaker/ad board, honorarium

    Gavin Bart, MD, PhD, FASAM, FACP

    Nothing to Disclose

    Susan Kaye Blank, MD, DFASAM

    Nothing to Disclose

    Michael A. Dekker, DO

    Nothing to Disclose

    Christina M. Delos Reyes, MD, FASAM

    Nothing to Disclose

    Michael Fingerhood, MD, FACP

    Nothing to Disclose

    Peter David Friedmann, MD, MPH, FACP, DFASAM

    Alkermes: In-Kind Support, Research; Orexo: Honoraria, Facilitated roundtable; Indivior: Honoraria, Advisory Board

    Adam J. Gordon, MD, MPH, FACP, CMRO, DFASAM

    Nothing to Disclose

    Joshua D. Lee, MD MSc

    Does Disclose

    Michelle Lofwall, MD, DFASAM

    Does Disclose

    Joseph Montgomery Matta, MD, FASAM

    Nothing to Disclose

    Mark P. Schwartz, MD, FASAM

    Nothing to Disclose

    Sarah E. Wakeman, MD

    Nothing to Disclose

    Mark A. Weiner, MD, DFASAM

    Nothing to Disclose

    Norman Wetterau, MD, FAAFP, DFASAM

    Nothing to Disclose

    CME Committee

    Name

    Disclosure Information

    Adam J. Gordon, MD, MPH, FACP, FASAM, CMRO, Chair, Reviewer

    Nothing to Disclose

    Catherine Friedman, MD

    Vice Chair

    Nothing to Disclose

    Noel Ilogu, MD, MRCP

    Nothing to Disclose

    Hebert L. Malinoff, MD, FACP, FASAM

    Nothing to Disclose

    Edwin A. Salsitz, MD, FASAM, Reviewer

    Nothing to Disclose

    John C. Tanner, DO, FASAM, CCFC, MRO

    Reckitt-Benckiser: Honorarium, Speaker; Orexo: Honorarium, Speaker; BDSI: Honorarium, Speaker & Consultant

    Learning Objectives

    At the conclusion of the conference, participants should be able to:

    • Employ current and new clinical approaches to treatment in a variety of settings.
    • Utilize and promote evidence-based approaches for clinical treatment of substance abuse disorders.
    • Recognize issues that arise when treating individuals in diverse and special populations or with special physical, health and mental illnesses.
    • Identify, diagnose, and treat substance use disorders in clinical populations.
    • Describe the development of new science and treatments in addiction medicine.

    Accreditation Council for Continuing Medical Education

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    ASAM has designated this enduring material for a maximum of 69 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABAM Maintenance of Certification Program (MOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 69 AMA PRA Category 1 Credits for completing the ASAM 47th Annual Conference and Pre-Courses.

    Who should attend:
    • Physicians and Clinicians
    • Researchers and Academics
    • Counselors and Students
    • Other Health Care Professionals

    Dedicated to increasing access and improving the quality of addiction treatment and care.

    • Register
      • Regular Member - $650
      • Retired - $650
      • Early Career Physician - $650
      • Resident - $400
      • Student - $400
      • Associate - $400
      • ASAM Staff - Free!
      • Non-Member - $850
      • International Member - $650
      • Emeritus Member - $650
      • Provisional Member - $650
      • Fellow Member - $650
      • Honorary Member - $650
    • More Information

UPCOMING LIVE

The ASAM State of the Art Course in Addiction Medicine

October 6 - 8, 2016 | Washington Hilton | Washington, DC


The ASAM 48th Annual Conference - Innovations in Addiction Medicine and Science

April 6-9, 2017 | New Orleans Hilton | New Orleans, LA